Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Borg

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of Medical Biography|November 17, 2010
James Blundell MD Edin FRCP (1790-1877): pioneer of blood transfusionMatthew Welck, Philip Borg, Harold Ellis
Endoscopy|November 28, 2024
Unlicensed stent use creating the need for additional proceduresHans-Ulrich Laasch, Philip Borg, Damian Mullan
The Oncologist|March 27, 2019
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET StudyAngela Lamarca, Joakim Crona, Maxime Ronot, et al.
Neuroendocrinology|July 28, 2020
Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of VariabilityClarisse Dromain, Anders Sundin, Pavan Najran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 StudyAngela Lamarca, Maxime Ronot, Salma Moalla, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of Medical Biography|November 17, 2010
James Blundell MD Edin FRCP (1790-1877): pioneer of blood transfusionMatthew Welck, Philip Borg, Harold Ellis
Endoscopy|November 28, 2024
Unlicensed stent use creating the need for additional proceduresHans-Ulrich Laasch, Philip Borg, Damian Mullan
The Oncologist|March 27, 2019
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET StudyAngela Lamarca, Joakim Crona, Maxime Ronot, et al.
Neuroendocrinology|July 28, 2020
Tumor Growth Rate to Predict the Outcome of Patients with Neuroendocrine Tumors: Performance and Sources of VariabilityClarisse Dromain, Anders Sundin, Pavan Najran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 StudyAngela Lamarca, Maxime Ronot, Salma Moalla, et al.
Pageof 1